ADVA
11.11.2021 09:02:09 CET | Business Wire | Press release
ADVA (FSE: ADV) today launched its FSP 3000 OpenFabric1200™ solution to help network operators significantly reduce metro costs. The OTN-based technology enables client services to be groomed into 400Gbit/s wavelengths, maximizing fiber capacity and supporting cost-efficient coherent networks. The latest member of the FSP 3000 OpenFabric™ Series combines open 400Gbit/s pluggable coherent technology with OTN switching on a blade, increasing wavelength efficiency. The open switchponder card can be added to any network without requiring additional adaptors. Specifically engineered for the 400Gbit/s era, the ADVA FSP 3000 OpenFabric1200™ features 1200Gbit/s interface capacity and supports Ethernet and OTN services from 10Gbit/s to 400Gbit/s.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211111005220/en/
“The strain on today’s transport infrastructure is growing like never before. Today’s operators need new solutions that can meet rapidly rising data demand while also driving down costs. That’s why we’ve developed our FSP 3000 OpenFabric1200™ . It offers a simple way to dramatically increase fiber efficiency by supporting lower-speed service grooming at the network edge. By deploying OpenFabric1200™ in ring or hub-and-spoke topologies, operators can significantly reduce switching and cross-connect requirements in the core,” said Christoph Glingener, CTO, ADVA. “What’s more, our open Terabit-scale switchponder solution can be easily added to any network.”
The new technology is part of the ADVA FSP 3000 OpenFabric™ Series, a family of switchponders built for maximum openness, flexibility and scale. The OpenFabric1200™ offers OTN switching with the benefits of open CFP2 pluggable coherent interfaces. With Terabit capacity, the new card is the ideal tool for leveraging more value from deployed metro infrastructure and upgrading legacy networks to the latest coherent pluggable technology. The FSP 3000 OpenFabric1200™ can work in multiple operation modes: ADM on a blade, DWDM muxponders, or OTN cross-connect. What’s more, thanks to its open design, client services can be connected directly or via standard OTN-based transponders without the need for any adapters.
“Our FSP 3000 OpenFabric1200™ will be a key tool in tackling skyrocketing bandwidth demand while supporting existing low-speed services. The technology takes our OpenFabric™ concept to the next level, enabling traffic grooming at the edge where it’s most efficient and delivering 1.2Tbit/s interface capacity. It offers the power to adapt to changing traffic demands without a hardware upgrade while simplifying operations and enabling network operators to scale as and when needed,” commented Cornelius Fürst, director, product line management, ADVA. “Our FSP 3000 OpenFabric1200™ is the flexible OTN solution that’s about to switch things up. For metro network operators, our new switchponder opens the door to the benefits of disaggregated environments and the latest pluggable coherent 400Gbit/s technology.”
Watch this video for more information on the FSP 3000 OpenFabric1200™: https://youtu.be/ti101PI1fxw .
Further details are also available in these slides: https://adva.li/fsp-3000-openfabric1200-slides .
A supporting solution brief can be downloaded here: https://adva.li/fsp-3000-openfabric-series-solution-brief .
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com
.
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20211111005220/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release
SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom